Center-Authored Papers

Filters: Author is Klotz, Laurence  [Clear All Filters]
Journal Article
Delahunt B, Hammond E, Egevad L, Samaratunga H, Srigley JR, Humphrey PA, Rubin M, Epstein JI, Lin DW, Gore JL et al..  2015.  Active surveillance for prostate cancer: the role of the pathologist.. Pathology. 47(1):1-3.
Amin MB, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin M, Nacey J, Carter BH, Klotz L et al..  2014.  The Critical Role of the Pathologist in Determining Eligibility for Active Surveillance as a Management Option in Patients With Prostate Cancer: Consensus Statement With Recommendations Supported by the College of American Pathologists, International Soci. Archives of pathology & laboratory medicine. Abstract
Klotz L, Nabid A, Higano C, Ryanm C, Kebabdjian M, Chin J.  2014.  Effect of dutasteride in men receiving intermittent androgen ablation therapy: The AVIAS trial.. Canadian Urological Association journal = Journal de l'Association des urologues du Canada. 8(11-12):E789-94. Abstract
Klotz L, Higano CS.  2016.  Intermittent Androgen Deprivation Therapy-An Important Treatment Option for Prostate Cancer.. JAMA oncology.
Klotz L, O'Callaghan C, Ding K, Toren P, Dearnaley D, Higano CS, Horwitz E, Malone S, Goldenberg L, Gospodarowicz M et al..  2015.  Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(10):1151-6. Abstract
Klein EA, Thompson IM, Tangen CM, Crowley J, Lucia SM, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano MJ et al..  2011.  Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).. JAMA : the journal of the American Medical Association. 306(14):1549-56. Abstract